Favrille, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies for the treatment of cancer and other diseases of the immune system. It offers FavId, which is in Phase III clinical trials, for the treatment of B-cell non-Hodgkin’s lymphoma. The company’s technology enables in manufacturing immunotherapy products that are designed to stimulate a patient’s immune system to mount a specific and sustained response to diseases. It also develops FAV-201 for the treatment of T-cell lymphoma. In addition, the company intends to initiate preclinical studies to identify additional product candidates for the treatment of...